Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?

Genet Med. 2015 Jan;17(1):21-3. doi: 10.1038/gim.2014.79. Epub 2014 Jul 10.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Enzyme Replacement Therapy
  • Fabry Disease / drug therapy*
  • Humans
  • Isoenzymes / administration & dosage*
  • Recombinant Proteins
  • alpha-Galactosidase / administration & dosage*

Substances

  • Isoenzymes
  • Recombinant Proteins
  • agalsidase alfa
  • alpha-Galactosidase
  • agalsidase beta